ArticleWorld journal of surgical oncology2025
miR-4793-3p predicts poor prognosis and regulates ferroptosis and invasiveness of breast cancer via targeting RNF169.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lymph node metastasis-related circHELQ promotes progression and acts as a nanotherapeutic target in colorectal cancer.Journal of nanobiotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundThe prognosis prediction of breast cancer is a challenging problem in the clinic. Identifying reliable biomarkers and revealing the regulatory mechanism underlying the progression of breast cancer cells would benefit the treatment and outcomes of breast cancer patients.
objectivesThis study aims to explore a novel biomarker related with tumor progression and clinical prognosis, focusing on miR-4793-3p and its targets. MATERIALS AND
methodsThe study enrolled 133 patients with breast cancer, and tissue samples were obtained. Expression of miR-4793-3p and its clinical significance were evaluated from the perspective of molecular subtypes, disease development, and prognosis. The regulatory effect and mechanism of miR-4793-3p in the biological function of breast cancer cells were assessed.
resultsSignificant downregulation of miR-4793-3p was observed in tumor tissues of patients with breast cancer, and lower miR-4793-3p levels were found in patients with more malignant subtypes. miR-4793-3p was closely associated with the differentiation, TNM stage, lymph node metastasis, subtypes, and poor prognosis of patients and was identified as an independent prognostic factor. miR-4793-3p significantly suppressed cell growth, metastatic potential, and promoted ferroptosis of breast cancer, and the negative regulation of RNF169 was revealed to mediate the function of miR-4793-3p. JAK2/STAT3 signaling was suppressed by miR-4793-3p, which suppressed cell growth and metastatic potential and promoted ferroptosis.
conclusionmiR-4793-3p could act as a biomarker for breast cancer, indicating cancer development and predicting patients' outcomes. miR-4793-3p modulated ferroptosis and therefore regulated tumor progression via suppressing JAK2/STAT3 signaling by targeting RNF169.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.